Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Exclusivity

The articles shown below are all about the Exclusivity, through these related articles, you can get relevant information, notes in use, or latest trends about the Exclusivity. We hope these news will give you the help you need. And if these Exclusivity articles can't solve your needs, you can contact us for relevant information.
  • Drug Patent & Exclusivity Expiration Report - Week of Aug 11 2025

    2025-08-11

    This week, there are 6 drugs in the patent and exclusivity list. They are: - NOVO NORDISK INC's OZEMPIC, containing active ingredient SEMAGLUTIDE - NOVO NORDISK INC's VICTOZA, containing active ingredient LIRAGLUTIDE - NOVO NORDISK INC's SAXENDA, containing active ingredient LIRAGLUTIDE - NIPPON SHINYAKU CO LTD's VILTEPSO, containing active ingredient VILTOLARSEN - VERTEX PHARMACEUTICALS INC's KALYDECO, containing active ingredient IVACAFTOR - EISAI INC's LENVIMA, containing active ingredient LENVATINIB MESYLATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Aug 04 2025

    2025-08-04

    This week, there are 9 drugs in the patent and exclusivity list. They are: - BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB - GILEAD SCIENCES INC's ZYDELIG, containing active ingredient IDELALISIB - SUMITOMO PHARMA SWITZERLAND GMBH's MYFEMBREE, containing active ingredient ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - BAYER HEALTHCARE PHARMACEUTICALS INC's NUBEQA, containing active ingredient DAROLUTAMIDE - BAYER HEALTHCARE PHARMACEUTICALS INC's LAMPIT, containing active ingredient NIFURTIMOX - VERTEX PHARMACEUTICALS INC's ORKAMBI, containing active ingredient IVACAFTOR; LUMACAFTOR - GENENTECH INC's EVRYSDI, containing active ingredient RISDIPLAM - ALNYLAM PHARMACEUTICALS INC's ONPATTRO, containing active ingredient PATISIRAN SODIUM - AMICUS THERAPEUTICS US LLC's GALAFOLD, containing active ingredient MIGALASTAT HYDROCHLORIDE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of July 28 2025

    2025-07-28

    This week, there are 4 drugs in the patent and exclusivity list. They are: - GILEAD SCIENCES INC's LIVDELZI, containing active ingredient SELADELPAR LYSINE - ABBVIE INC's KYBELLA, containing active ingredient DEOXYCHOLIC ACID - GENENTECH INC's COTELLIC, containing active ingredient COBIMETINIB FUMARATE - ARCUTIS BIOTHERAPEUTICS INC's ZORYVE, containing active ingredient ROFLUMILAST Read More
  • Drug Patent & Exclusivity Expiration Report - Week of July 21 2025

    2025-07-21

    This week, there are 12 drugs in the patent and exclusivity list. They are: - NEURELIS INC's VALTOCO, containing active ingredient DIAZEPAM - DUCHESNAY INC's OSPHENA, containing active ingredient OSPEMIFENE - GILEAD SCIENCES INC's ZYDELIG, containing active ingredient IDELALISIB - SUN PHARMACEUTICAL INDUSTRIES LTD's WINLEVI, containing active ingredient CLASCOTERONE - SENTYNL THERAPEUTICS INC's ZOKINVY, containing active ingredient LONAFARNIB - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's TRELEGY ELLIPTA, containing active ingredient FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's ANORO ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE's INCRUSE ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE - GILEAD SCIENCES INC's VEKLURY, containing active ingredient REMDESIVIR Read More
  • Drug Patent & Exclusivity Expiration Report - Week of July 14 2025

    2025-07-14

    This week, there are 6 drugs in the patent and exclusivity list. They are: - NOVARTIS PHARMACEUTICALS CORP's ENTRESTO, containing active ingredient SACUBITRIL; VALSARTAN - BIOCODEX SA's DIACOMIT, containing active ingredient STIRIPENTOL - PF PRISM CV's XALKORI, containing active ingredient CRIZOTINIB - INCYTE CORP's OPZELURA, containing active ingredient RUXOLITINIB PHOSPHATE - SERVIER PHARMACEUTICALS LLC's TIBSOVO, containing active ingredient IVOSIDENIB - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's KRINTAFEL, containing active ingredient TAFENOQUINE SUCCINATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of July 07 2025

    2025-07-07

    This week, there are 13 drugs in the patent and exclusivity list. They are: - GILEAD SCIENCES INC's BIKTARVY, containing active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's ODEFSEY, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's VEMLIDY, containing active ingredient TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's GENVOYA, containing active ingredient COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's DESCOVY, containing active ingredient EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - FRESENIUS KABI USA LLC's OMEGAVEN, containing active ingredient FISH OIL TRIGLYCERIDES - ANI PHARMACEUTICALS INC's VEREGEN, containing active ingredient SINECATECHINS - NOVARTIS PHARMACEUTICALS CORP's PROMACTA KIT, containing active ingredient ELTROMBOPAG OLAMINE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of June 30 2025

    2025-06-30

    This week, there are 4 drugs in the patent and exclusivity list. They are: - ASTRAZENECA AB's FARXIGA, containing active ingredient DAPAGLIFLOZIN - EAGLE PHARMACEUTICALS INC's RYANODEX, containing active ingredient DANTROLENE SODIUM - ULTRAGENYX PHARMACEUTICAL INC's DOJOLVI, containing active ingredient TRIHEPTANOIN - VIIV HEALTHCARE CO's RUKOBIA, containing active ingredient FOSTEMSAVIR TROMETHAMINE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of June 23 2025

    2025-06-23

    This week, there are 18 drugs in the patent and exclusivity list. They are: - SUNOVION PHARMACEUTICALS INC's LATUDA, containing active ingredient LURASIDONE HYDROCHLORIDE - VERTEX PHARMACEUTICALS INC's TRIKAFTA (COPACKAGED), containing active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - VERTEX PHARMACEUTICALS INC's KALYDECO, containing active ingredient IVACAFTOR - VERTEX PHARMACEUTICALS INC's SYMDEKO (COPACKAGED), containing active ingredient IVACAFTOR; IVACAFTOR, TEZACAFTOR - TAKEDA PHARMACEUTICALS USA INC's KAZANO, containing active ingredient ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - VERTEX PHARMACEUTICALS INC's ALYFTREK, containing active ingredient DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM Read More
  • Drug Patent & Exclusivity Expiration Report - Week of June 16 2025

    2025-06-16

    This week, there are 9 drugs in the patent and exclusivity list. They are: - BRISTOL MYERS SQUIBB CO's POMALYST, containing active ingredient POMALIDOMIDE - VIATRIS SPECIALTY LLC's TOBI PODHALER, containing active ingredient TOBRAMYCIN - RHYTHM PHARMACEUTICALS INC's IMCIVREE, containing active ingredient SETMELANOTIDE ACETATE - PF PRISM CV's BOSULIF, containing active ingredient BOSUTINIB MONOHYDRATE - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - BPI LABS LLC's ABLYSINOL, containing active ingredient ALCOHOL - HORIZON THERAPEUTICS USA INC's PROCYSBI, containing active ingredient CYSTEAMINE BITARTRATE - NOVARTIS PHARMACEUTICALS CORP's TAFINLAR, containing active ingredient DABRAFENIB MESYLATE - NOVARTIS PHARMACEUTICALS CORP's MEKINIST, containing active ingredient TRAMETINIB DIMETHYL SULFOXIDE Read More
  • Total 5 pages  Go to Page
  • Go